CoChat
Sign Up
Cited by 18Peripheral Artery Disease ManagementRNA modifications and cancerPlatelet Disorders and Treatments

Plasma levels of snoRNAs are associated with platelet activation in patients with peripheral artery disease

Open access
Nossent, Anne Yaël, Ektefaie, Neda, Wojta, Johann, Eichelberger, Beate, Kopp, Christoph, Panzer, Simon, Gremmel, Thomas·2019·International Journal of Molecular Sciences
DOI 10.3390/ijms20235975PMC PMC6929168
Open this paper in CoChat — free accountOpen PDF

Abstract

In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and bypass surgery, respectively. Both are associated with a high restenosis rate. Furthermore, patients with PAD often suffer atherothrombotic events like myocardial infarction, transient ischemic attacks or stroke. Small ribonucleic acids (RNAs) have proven reliable biomarkers because of their remarkable stability. Small nucleolar RNAs (snoRNAs) guide modifications to small nuclear RNAs and ribosomal RNAs, enabling protein synthesis. In the current study, we measured four snoRNAs in 104 consecutive PAD patients who underwent elective infrainguinal angioplasty with stent implantation. We selected snoRNAs that showed significant overexpression in the plasma of end-stage PAD patients in a previous study. All four snoRNAs are transcribed from the 14q32 locus, which is strongly linked to human cardiovascular disease, including PAD and restenosis. We showed that the four selected 14q32 snoRNAs were abundantly expressed in the plasma of PAD patients. The plasma levels of these snoRNAs were not directly associated with target vessel restenosis, however, levels of SNORD113.2 and SNORD114.1 were strongly linked to platelet activation, which is an important determinant of long-term outcome, in PAD, and in cardiovascular disease in general.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20235975

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The authors have not been able to find a report that SNORD115 or individual members of the SNORD115 cluster were released in plasma EV of patients with lung cancer.

    “However, we have not been able to find a report that SNORD115 or individual members of SNORD115 cluster were released in plasma EV of patients with lung cancer (Nossent et al., 2019; Steinbusch et al., 2017).”

    From Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer's disease (2021) · cites this paper as Nossent et al., 2019

    The Results (section 2.1) and Methods (section 4.7; page numbers unavailable) concern plasma SNORD112, SNORD113.2, SNORD113.6, and SNORD114.1 in patients with peripheral artery disease. Searches for SNORD115, extracellular vesicles, and lung cancer found no passage addressing whether a report of SNORD115 release in plasma EV exists. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. [1]Hiatt W.R. Goldstone J. Smith S.C. Jr. McDermott M. Moneta G. Oka R. Newman A.B. Pearce W.H. American Heart Association Writing Group 1 Atherosclerotic Peripheral Vascular Disease Symposium II: Nomenclature for vascular diseases Circulation 2008 118 2826 2829 10.1161/CIRCULATIONAHA.108.191171 19106403 · DOI
  2. [2]Hiatt W.R. Armstrong E.J. Larson C.J. Brass E.P. Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease Circ. Res. 2015 116 1527 1539 10.1161/CIRCRESAHA.116.303566 25908726 · DOI
  3. [3]Jukema J.W. Verschuren J.J. Ahmed T.A. Quax P.H. Restenosis after PCI. Part 1: Pathophysiology and risk factors Nat. Rev. Cardiol. 2011 9 53 62 10.1038/nrcardio.2011.132 21912414 · DOI
  4. [4]Lee A.J. Price J.F. Russell M.J. Smith F.B. van Wijk M.C. Fowkes F.G. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: The Edinburgh Artery Study Circulation 2004 110 3075 3080 10.1161/01.CIR.0000143102.38256.DE 15477416 · DOI
  5. [5]Diehm C. Lange S. Darius H. Pittrow D. von Stritzky B. Tepohl G. Haberl R.L. Allenberg J.R. Dasch B. Trampisch H.J. Association of low ankle brachial index with high mortality in primary care Eur. Heart J. 2006 27 1743 1749 10.1093/eurheartj/ehl092 16782720 · DOI
  6. [6]Stojkovic S. Jurisic M. Kopp C.W. Koppensteiner R. Huber K. Wojta J. Gremmel T. Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation Atherosclerosis 2018 269 197 203 10.1016/j.atherosclerosis.2018.01.020 29366993 · DOI
  7. [7]Stather P.W. Sylvius N. Wild J.B. Choke E. Sayers R.D. Bown M.J. Differential microRNA expression profiles in peripheral arterial disease Circ. Cardiovasc. Genet. 2013 6 490 497 10.1161/CIRCGENETICS.111.000053 24129592 · DOI
  8. [8]Mitchell P.S. Parkin R.K. Kroh E.M. Fritz B.R. Wyman S.K. Pogosova-Agadjanyan E.L. Peterson A. Noteboom J. O’Briant K.C. Allen A. Circulating microRNAs as stable blood-based markers for cancer detection Proc. Natl. Acad. Sci. USA 2008 105 10513 10518 10.1073/pnas.0804549105 18663219 PMC2492472 · DOI · Paper page
  9. [9]Hakansson K.E.J. Sollie O. Simons K.H. Quax P.H.A. Jensen J. Nossent A.Y. Circulating Small Non-coding RNAs as Biomarkers for Recovery After Exhaustive or Repetitive Exercise Front. Physiol. 2018 9 1136 10.3389/fphys.2018.01136 30246800 PMC6113669 · DOI
  10. [10]Hakansson K.E.J. Goossens E.A.C. Trompet S. van Ingen E. de Vries M.R. van der Kwast R. Ripa R.S. Kastrup J. Hohensinner P.J. Kaun C. Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in Human Cardiovascular Disease Cardiovasc. Res. 2018 10.1093/cvr/cvy309 30544252 · DOI
  11. [11]Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs EMBO J. 2001 20 3617 3622 10.1093/emboj/20.14.3617 11447102 PMC125535 · DOI
  12. [12]Wezel A. Welten S.M. Razawy W. Lagraauw H.M. de Vries M.R. Goossens E.A. Boonstra M.C. Hamming J.F. Kandimalla E.R. Kuiper J. Inhibition of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and Increases Plaque Stability Ann. Surg. 2015 262 841 847 discussion 847–848 10.1097/SLA.0000000000001466 26583674 · DOI
  13. [13]Welten S.M. Bastiaansen A.J. de Jong R.C. de Vries M.R. Peters E.A. Boonstra M.C. Sheikh S.P. La Monica N. Kandimalla E.R. Quax P.H. Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494 and miR-495 increases neovascularization and blood flow recovery after ischemia Circ. Res. 2014 115 696 708 10.1161/CIRCRESAHA.114.304747 25085941 · DOI
  14. [14]Welten S.M. Goossens E.A. Quax P.H. Nossent A.Y. The multifactorial nature of microRNAs in vascular remodelling Cardiovasc. Res. 2016 110 6 22 10.1093/cvr/cvw039 26912672 · DOI
  15. [15]Welten S.M.J. de Jong R.C.M. Wezel A. de Vries M.R. Boonstra M.C. Parma L. Jukema J.W. van der Sluis T.C. Arens R. Bot I. Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis Atherosclerosis 2017 261 26 36 10.1016/j.atherosclerosis.2017.04.011 28445809 · DOI
  16. [16]Nossent A.Y. Eskildsen T.V. Andersen L.B. Bie P. Bronnum H. Schneider M. Andersen D.C. Welten S.M. Jeppesen P.L. Hamming J.F. The 14q32 microRNA-487b targets the antiapoptotic insulin receptor substrate 1 in hypertension-induced remodeling of the aorta Ann. Surg. 2013 258 743 751 discussion 752–743 10.1097/SLA.0b013e3182a6aac0 24096771 · DOI
  17. [17]Welten G.M. Schouten O. Hoeks S.E. Chonchol M. Vidakovic R. van Domburg R.T. Bax J.J. van Sambeek M.R. Poldermans D. Long-term prognosis of patients with peripheral arterial disease: A comparison in patients with coronary artery disease J. Am. Coll. Cardiol. 2008 51 1588 1596 10.1016/j.jacc.2007.11.077 18420103 · DOI
  18. [18]Gremmel T. Xhelili E. Steiner S. Koppensteiner R. Kopp C.W. Panzer S. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty Atherosclerosis 2014 232 119 124 10.1016/j.atherosclerosis.2013.10.027 24401225 · DOI
  19. [19]Xi S. Xu H. Shan J. Tao Y. Hong J.A. Inchauste S. Zhang M. Kunst T.F. Mercedes L. Schrump D.S. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis J. Clin. Investig. 2013 123 1241 1261 10.1172/JCI61271 23426183 PMC3582115 · DOI
  20. [20]Gremmel T. Steiner S. Seidinger D. Koppensteiner R. Panzer S. Kopp C.W. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy Thromb. Res. 2009 124 588 591 10.1016/j.thromres.2009.06.012 19631365 · DOI
  21. [21]Bliden K.P. Dichiara J. Lawal L. Singla A. Antonino M.J. Baker B.A. Bailey W.L. Tantry U.S. Gurbel P.A. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J. Am. Coll. Cardiol. 2008 52 531 533 10.1016/j.jacc.2008.04.045 18687246 · DOI
  22. [22]Badrnya S. Schrottmaier W.C. Kral J.B. Yaiw K.C. Volf I. Schabbauer G. Soderberg-Naucler C. Assinger A. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation Arterioscler. Thromb. Vasc. Biol. 2014 34 571 580 10.1161/ATVBAHA.113.302919 24371083 · DOI
  23. [23]van Ingen E. Foks A.C. Kröner M.J. Kuiper J. Quax P.H.A. Bot I. Nossent A.Y. Antisense Oligonucleotide Inhibition of MicroRNA-494 Halts Atherosclerotic Plaque Progression and Promotes Plaque Stabilization Mol. Ther. Nucleic Acids 2019 18 638 649 10.1016/j.omtn.2019.09.021 31689618 PMC6838792 · DOI
  24. [24]Edelstein L.C. Simon L.M. Montoya R.T. Holinstat M. Chen E.S. Bergeron A. Kong X. Nagalla S. Mohandas N. Cohen D.E. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c Nat. Med. 2013 19 1609 1616 10.1038/nm.3385 24216752 PMC3855898 · DOI
  25. [25]Jorjani H. Kehr S. Jedlinski D.J. Gumienny R. Hertel J. Stadler P.F. Zavolan M. Gruber A.R. An updated human snoRNAome Nucleic. Acids. Res. 2016 44 5068 5082 10.1093/nar/gkw386 27174936 PMC4914119 · DOI · Paper page
  26. [26]Gremmel T. Steiner S. Seidinger D. Koppensteiner R. Panzer S. Kopp C.W. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation Thromb. Haemost. 2014 111 474 482 10.1160/TH13-07-0558 24196591 · DOI
  27. [27]Gremmel T. Steiner S. Seidinger D. Koppensteiner R. Panzer S. Kopp C.W. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb. Haemost. 2009 101 333 339 19190818
  28. [28]Gremmel T. Koppensteiner R. Panzer S. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists—Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy PLoS ONE 2015 10 e0129666 10.1371/journal.pone.0129666 26058047 PMC4461164 · DOI
  29. [29]Gremmel T. Ay C. Riedl J. Kopp C.W. Eichelberger B. Koppensteiner R. Panzer S. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis Thromb. Haemost. 2016 115 615 621 10.1160/TH15-07-0598 26467184 · DOI
  30. [30]Gremmel T. Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel Thromb. Haemost. 2011 106 211 218 10.1160/TH11-03-0137 21614418 · DOI
  31. [31]Cavaille J. Seitz H. Paulsen M. Ferguson-Smith A.C. Bachellerie J.P. Identification of tandemly-repeated C/D snoRNA genes at the imprinted human 14q32 domain reminiscent of those at the Prader-Willi/Angelman syndrome region Hum. Mol. Genet. 2002 11 1527 1538 10.1093/hmg/11.13.1527 12045206 · DOI

Cited by

Sorted by citations

Authors
Nossent, A. Y., Ektefaie, N., Wojta, J., Eichelberger, B., Kopp, C., Panzer, S., & Gremmel, T.
Affiliations
  • Leiden University Medical Center (NL)
  • Medical University of Vienna (AT)
  • Ludwig Boltzmann Institute for Cardiovascular Research (AT)
  • Universitätsklinikum Wiener Neustadt (AT)
Corresponding author
Gremmel, Thomas
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-11-27
Volume
20
Issue
23
Pages
5975
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms20235975
PMC
PMC6929168
OpenAlex
W2991066898
Cited by
18
References
0
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2
FWCI
0.96
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
Austrian Science Fund (M2578-B30)
Topics
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
peripheral arterial disease, small nucleolar RNA, platelet activation, plasma biomarkers, restenosis, atherothrombosis
MeSH terms
Ischemic Attack, Transient, Female, Humans, Male, Myocardial Infarction, Plasma, Prospective Studies, Risk Factors, Platelet Activation, Stroke, RNA, Small Nucleolar, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review